Core Viewpoint - The Oncology Institute, Inc. (TOI) has amended its facility agreement with Deerfield Management Company, allowing for greater financial flexibility and a partial paydown of senior secured convertible notes [1][2][3]. Financial Agreement - Deerfield has waived certain restrictions on TOI's ability to offer and sell equity and removed the minimum cash covenant of $40 million [2]. - TOI has paid down approximately $20 million of the senior secured convertible notes along with accrued and unpaid interest [2]. Growth Initiatives - TOI has signed three new capitation agreements year to date, adding approximately 80,000 lives across California, Nevada, and Florida [3]. - The total lives under value-based agreements in Florida now exceed 200,000, with over 50,000 under Medicare Advantage [3]. Company Overview - Founded in 2007, TOI is a leading provider of value-based cancer care in the community setting, serving over 1.8 million patients [4]. - The company employs over 120 clinicians and has more than 700 teammates across over 70 clinic locations [4].

Group 1 - Topicus.com Inc. plans to release its fourth quarter results on February 26, 2025 [1] - The quarterly results will be available via press release and on the Company's website and SEDAR website after market close on the release date [1] - Topicus' subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI" [2] Group 2 - Topicus specializes in acquiring, managing, and building vertical market software businesses [2]

Group 1 - Topicus.com Inc. has announced the acquisition of 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share from Cyfrowy Polsat S.A. [1] - Topicus.com Inc.'s subsidiaries Yukon Niebieski Kapital B.V. and TSS Europe B.V. have signed a shareholders' agreement with the Adam Góral Family Foundation to govern their cooperation regarding their shareholdings in Asseco Poland S.A. [1] - The shareholders' agreement will take effect upon the completion of Yukon's acquisition of 12,318,863 treasury shares from Asseco Poland S.A., representing 14.84% of the company's share capital, also at a price of 85 PLN per share [1] Group 2 - Asseco Group operates in the information technology sector and has a presence in 62 countries, offering proprietary IT solutions across various economic sectors [3] - The Adam Góral Family Foundation, established by the CEO of Asseco Poland, operates under the Polish Family Foundation Act and is registered in Rzeszów, Poland [4] - Topicus.com Inc. is a leading provider of vertical market software in Europe, focusing on acquiring and managing software companies that provide specialized solutions for public and private sector clients [5]

Group 1 - Topicus.com Inc. announced the acquisition of 8,300,029 shares in Asseco Poland S.A. from Cyfrowy Polsat S.A., representing approximately 9.99% of the issued shares in Asseco Poland S.A. at a price of 85 PLN per share [1] - Asseco Group operates in 62 countries and is engaged in information technology, offering comprehensive IT solutions for all sectors of the economy [2] - Topicus.com Inc. is a pan-European provider of vertical market software and platforms, focusing on long-term growth potential in various European markets [3] Group 2 - Cyfrowy Polsat S.A. is a leading media and telecom group in Poland, providing digital pay-TV, telephony, broadband internet, and operating in renewable energy [4]

Core Insights - Florida Blue has launched a new oncology care model aimed at improving access to high-quality cancer care for its myBlue members, developed in collaboration with Sanitas Medical Centers and The Oncology Institute [1][4] - The program focuses on personalized, evidence-based treatment plans and emphasizes collaboration between oncologists and primary care providers to enhance patient outcomes and overall health [3][4] Company Overview - Florida Blue is the leading health insurer in Florida, serving over six million members across all 67 counties and has been in operation for more than 80 years [6] - The Oncology Institute is a prominent value-based oncology group in the U.S., providing high-quality cancer care at 14 locations in Central and South Florida [2][12] - Sanitas Medical Centers offers comprehensive primary care to nearly half a million Florida Blue members through 60 locations [2] Program Details - The new oncology care model connects myBlue members diagnosed with cancer to their own TOI oncology team, ensuring personalized treatment plans and support from primary care providers [3] - The program aims to facilitate seamless communication and coordination among healthcare providers, patients, and their families, enhancing the overall care experience [3][4] Enrollment Information - Individuals not currently enrolled in myBlue can sign up during the Marketplace open enrollment period, which ends on January 15, or at any time if they qualify for special enrollment [5]

Core Insights - Grapevine's digital supply chain solutions have enabled The Oncology Institute (TOI) to achieve over $1.7 million in medical supply savings year to date, with monthly savings reaching 61% in July 2024, highlighting the effectiveness of these innovations in healthcare [2][6]. Group 1: Cost Savings and Efficiency - The Oncology Institute's significant savings demonstrate the potential of Grapevine's digital procurement platform to eliminate inefficiencies in healthcare supply chains, ultimately reducing costs for patients [3][4]. - Grapevine's platform enhances the reliability and efficiency of healthcare supply chains by providing visibility into inventory levels, recommending alternative suppliers, and enabling seamless order tracking, which allows medical facilities to maintain high-quality care [5][6]. Group 2: Strategic Partnerships and Supplier Diversification - The partnership between Grapevine and TOI has allowed for a diversified supplier network, reducing reliance on single-source distributors and mitigating risks associated with supply shortages and inflated prices [4][7]. - By leveraging AI-driven procurement solutions, TOI has increased competition among suppliers, leading to lower costs and a more resilient supply chain [4][5]. Group 3: Industry Transformation - The success of Grapevine's platform underscores the importance of modernizing healthcare supply chains through digital transformation, promoting a future of cost-effective, resilient, and patient-centered care [6][7].

The Oncology Institute, Inc. (NASDAQ:TOI) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Operator Good afternoon and welcome to The Oncology Institute's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. At this time, I'd like to turn the conference over to Mark Hueppelsheuser, General Counsel at TOI. Thank you ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39248 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) (State or other jurisd ...

FOR IMMEDIATE RELEASE The Oncology Institute Reports Third Quarter 2024 Financial Results CERRITOS, Calif., November 13, 2024 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and nine months ended September 30, 2024. Recent Operational Highlights Include • 79.9% increase in Dispensary segment revenue compared to prior year quarter • Welcomed Rob Carter, as our ...

CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-68 ...